221 related articles for article (PubMed ID: 18982009)
1. Cost-effectiveness of pharmacological anti-obesity treatments: a systematic review.
Neovius M; Narbro K
Int J Obes (Lond); 2008 Dec; 32(12):1752-63. PubMed ID: 18982009
[TBL] [Abstract][Full Text] [Related]
2. What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review.
Ara R; Blake L; Gray L; Hernández M; Crowther M; Dunkley A; Warren F; Jackson R; Rees A; Stevenson M; Abrams K; Cooper N; Davies M; Khunti K; Sutton A
Health Technol Assess; 2012; 16(5):iii-xiv, 1-195. PubMed ID: 22340890
[TBL] [Abstract][Full Text] [Related]
3. Rimonabant for the treatment of overweight and obese people.
Burch J; McKenna C; Palmer S; Norman G; Glanville J; Sculpher M; Woolacott N
Health Technol Assess; 2009 Oct; 13 Suppl 3():13-22. PubMed ID: 19846024
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
5. The cost effectiveness of orlistat in a 1-year weight-management programme for treating overweight and obese patients in Sweden : a treatment responder approach.
Hertzman P
Pharmacoeconomics; 2005; 23(10):1007-20. PubMed ID: 16235974
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of orlistat for the treatment of overweight and obese patients in Ireland.
Lacey LA; Wolf A; O'shea D; Erny S; Ruof J
Int J Obes (Lond); 2005 Aug; 29(8):975-82. PubMed ID: 15852050
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of sibutramine in the treatment of obesity.
Warren E; Brennan A; Akehurst R
Med Decis Making; 2004; 24(1):9-19. PubMed ID: 15005950
[TBL] [Abstract][Full Text] [Related]
8. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement.
Avenell A; Broom J; Brown TJ; Poobalan A; Aucott L; Stearns SC; Smith WC; Jung RT; Campbell MK; Grant AM
Health Technol Assess; 2004 May; 8(21):iii-iv, 1-182. PubMed ID: 15147610
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacotherapy in the treatment of obesity].
Hamann A
MMW Fortschr Med; 2006 Mar; 148(9):36-8. PubMed ID: 16566392
[TBL] [Abstract][Full Text] [Related]
10. Long-term pharmacotherapy for obesity and overweight.
Padwal R; Li SK; Lau DC
Cochrane Database Syst Rev; 2003; (4):CD004094. PubMed ID: 14584004
[TBL] [Abstract][Full Text] [Related]
11. Assessment of clinical and economic benefits of weight management with sibutramine in general practice in Germany.
Brennan A; Ara R; Sterz R; Matiba B; Bergemann R
Eur J Health Econ; 2006 Dec; 7(4):276-84. PubMed ID: 17063345
[TBL] [Abstract][Full Text] [Related]
12. Cost-utility analysis of rimonabant in the treatment of obesity.
Hampp C; Hartzema AG; Kauf TL
Value Health; 2008; 11(3):389-99. PubMed ID: 18179661
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of a low-calorie diet and orlistat for obese persons: modeling long-term health gains through prevention of obesity-related chronic diseases.
van Baal PH; van den Berg M; Hoogenveen RT; Vijgen SM; Engelfriet PM
Value Health; 2008 Dec; 11(7):1033-40. PubMed ID: 18494748
[TBL] [Abstract][Full Text] [Related]
14. The effectiveness of pharmaceutical interventions for obesity: weight loss with orlistat and sibutramine in a United Kingdom population-based cohort.
Douglas IJ; Bhaskaran K; Batterham RL; Smeeth L
Br J Clin Pharmacol; 2015 Jun; 79(6):1020-7. PubMed ID: 25641659
[TBL] [Abstract][Full Text] [Related]
15. Obesity drug therapy.
Baretić M
Minerva Endocrinol; 2013 Sep; 38(3):245-54. PubMed ID: 24126545
[TBL] [Abstract][Full Text] [Related]
16. Obesity and cardiovascular physiology: impact of some pharmacological agents.
Chaput JP; Bérubé-Parent S; Tremblay A
Curr Vasc Pharmacol; 2005 Apr; 3(2):185-93. PubMed ID: 15853638
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacotherapy for obesity: current drugs and those in advanced development.
Halford JC
Curr Drug Targets; 2004 Oct; 5(7):637-46. PubMed ID: 15473253
[TBL] [Abstract][Full Text] [Related]
18. [Drug treatment of obesity].
Svendsen OL; Toubro S; Breum L; Bruun JM; Astrup AV
Ugeskr Laeger; 2006 Jan; 168(2):163-7. PubMed ID: 16403342
[TBL] [Abstract][Full Text] [Related]
19. Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis.
Johansson K; Neovius K; DeSantis SM; Rössner S; Neovius M
Obes Rev; 2009 Sep; 10(5):564-75. PubMed ID: 19460116
[TBL] [Abstract][Full Text] [Related]
20. Drugs in the treatment of obesity: sibutramine, orlistat and rimonabant.
Rubio MA; Gargallo M; Isabel Millán A; Moreno B
Public Health Nutr; 2007 Oct; 10(10A):1200-5. PubMed ID: 17903331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
